---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001062"
form_type: "8-K"
ticker: "SDEV"
cik: "0001389545"
company_name: "Stablecoin Development Corp"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:52:53.580218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NovaBay licenses Avenova brand to Sonoma for EU eye care market; royalty on Ocudox sales

## Summary
- Exclusive, non-transferable license to use Avenova brand with Sonoma's Ocudox and other eyecare products in the EU.
- Quarterly royalty based on net sales of Sonoma Products in the EU, minus returns, rebates, taxes, and delivery costs.
- License term is two years with automatic renewal and customary termination rights; either party may terminate for any reason with notice.
- Ocudox already has Class IIB CE mark for EU sale; Sonoma will manufacture and distribute through its EU distributor network.
- NovaBay remains exclusive U.S. seller of Avenova-branded products; EU market size comparable to U.S. provides expansion opportunity.

## SEC filing metadata
- accession: 0001437749-24-001062
- form_type: 8-K
- ticker: SDEV
- cik: 0001389545
- company_name: Stablecoin Development Corp
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1389545/000143774924001062/0001437749-24-001062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1389545/000143774924001062/nby20240108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001062
- JSON: https://secwatch.observer/filing/0001437749-24-001062.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001062.txt

## Key facts
- Material Agreements
  Stablecoin Development Corp entered into License Agreement with Sonoma Pharmaceuticals, Inc. (effective 2024-01-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Sonoma Pharmaceuticals, Inc.
  - Effective: 2024-01-05
  source text: NovaBay Pharmaceuticals, Inc. (“we,” “us,” “our” and “NovaBay”) entered into a License and Distribution Agreement, dated January 5, 2024 (the “License Agreement”), with Sonoma Pharmaceuticals, Inc. (“Sonoma”), pursuant to which we granted Sonoma an exclusive, non-transferable license to use our Avenova brand for use by Sonoma for the sale, distribution, and marketing of Sonoma’s eye product Ocudox® and its other eyecare products (“Sonoma Products”) in the European Union (the "Territory").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1389545/000143774924001062/0001437749-24-001062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.